[The survival analysis of the advanced metastatic castration-resistant prostate cancer].
OBJECTIVE
To analyze predictive factors of advanced metastatic castration-resistant prostate cancer.


METHODS
From December 1996 to March 2008, 250 cases of advanced metastatic prostate cancer progressed into the stage of hormonal independent prostate cancer. The last follow-up date was 31 March 2008 and the median follow-up time was 24 months. During the follow-up, 131 cases were alive, 105 cases were dead and 14 cases were lost to follow-up. Clinical and pathological information of the cases was analyzed to find the predictive factors that related to the prognosis.


RESULTS
The median survival time of advanced metastatic castration-resistant prostate cancer was 30 months, and the one-year, two-year, three-year survival rate was 79%, 59%, and 41%. The univariate analysis indicated that prostate specific antigen (PSA) at diagnosis, clinical stage, the PSA nadir during hormonal therapy, the time form the start of hormonal therapy to the PSA nadir, the time of response duration during hormonal therapy, PSA velocity (PSAV) and PSA doubling time (PSADT) at the emergency of castration-resistant prostate cancer, age and PSA at the diagnosis of castration-resistant prostate cancer were factors that predicted the survival time of advanced metastatic castration-resistant prostate cancer. The multivariate analysis indicated that the PSA nadir during hormonal therapy, the time form the start of hormonal therapy to the PSA nadir, PSAV at the emergency of castration-resistant prostate cancer, the time of response duration during hormonal therapy were independent factors that predicted the survival time of advanced metastatic castration-resistant prostate cancer.


CONCLUSIONS
The PSA nadir during hormonal therapy, the time form the start of hormonal therapy to the PSA nadir, PSAV at the emergency of castration-resistant prostate cancer and the time of response duration during hormonal therapy are independent factors that predict the survival time of advanced metastatic castration-resistant prostate cancer.
Ma
Chun-guang
CG
Department of Urology, Cancer Hospital, Fudan University, Shanghai 200032, China.
Ye
Ding-wei
DW
Yao
Xu-dong
XD
Zhang
Shi-lin
SL
Dai
Bo
B
Zhang
Hai-liang
HL
Zhu
Yao
Y
Shen
Yi-jun
YJ
Zhu
Yi-ping
YP
Shi
Guo-hai
GH
Qin
Xiao-jian
XJ
Lin
Guo-wen
GW
Yang
Li-feng
LF
Yang
Bo-shuai
BS
Xiao
Wen-jun
WJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*
D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen